Flecainide Use in Pregnancy: Evidence‑Based Recommendations

Guideline Recommendations

• The ACC/AHA/HRS guidelines assign flecainide a Class IIa recommendation (Level C‑LD) for ongoing management of highly symptomatic supraventricular tachycardia (SVT) in pregnant patients, positioning it as an acceptable second‑line option after first‑line agents such as digoxin, metoprolol, or propranolol. 1
• The 2011 ESC guidelines endorse flecainide for long‑term management of idiopathic sustained ventricular tachycardia when other anti‑arrhythmic drugs have failed, also with a Class IIa recommendation (Level C). 2

Patient Selection Criteria

• Flecainide should be prescribed only in patients with structurally normal hearts and no ischemic heart disease; this restriction is emphasized for pregnant women because of the added cardiovascular stress of pregnancy. 1
• The drug must not be used in patients with a prolonged QTc interval during pregnancy. 3

Timing Considerations During Pregnancy

• First‑trimester avoidance: All anti‑arrhythmic agents, including flecainide, are recommended to be avoided during the first trimester when the risk of congenital malformations is highest. 1
• Post‑first‑trimester use: After the first trimester, flecainide may be initiated or continued provided appropriate monitoring is in place. 1

Comparative Safety of Alternative Agents

• First‑line agents for pregnant SVT are digoxin, metoprolol, and propranolol; these should be trialed before flecainide unless contraindicated. 1
• Beta‑blockers (e.g., atenolol) carry a concern for intra‑uterine growth retardation, especially when used in the first trimester. 4, 1
• Sotalol is classified as FDA Pregnancy Category B, indicating a safer profile than flecainide’s Category C. 4
• Amiodarone is Class III (not recommended) in pregnancy because of a ~17 % incidence of fetal hypothyroidism. 1, 2
• Quinidine possesses the longest historical safety record for pharmacologic cardioversion in pregnancy. 5

Pharmacokinetic & Monitoring Considerations

• Pregnancy‑induced physiological changes (increased cardiac output, blood volume, reduced serum protein, and hepatic enzyme induction) alter flecainide absorption, bioavailability, and elimination, necessitating more frequent therapeutic drug monitoring and dose adjustments throughout gestation. 4, 6
• Monitoring protocol:
  
  • Obtain a baseline ECG and repeat periodically to detect QRS widening or QTc prolongation. 4
  • Measure plasma flecainide concentrations, especially as gestation advances, to guide dose titration. 4, 6

Contraindications & Common Pitfalls

• Flecainide must not be used as first‑line therapy; it should be reserved for patients who have failed or cannot tolerate safer alternatives such as digoxin or beta‑blockers. 1
• Absolute contraindications during pregnancy include structural heart disease, ischemic heart disease, and prolonged QTc interval. 1, 3
• Combination caution: Co‑administration of flecainide with AV‑node‑blocking agents (e.g., beta‑blockers) requires careful monitoring due to the risk of excessive conduction slowing. 4, 3

Medication Use in First Trimester Pregnancy

General Principles

• The American Heart Association recommends that all antiarrhythmic drugs and medications with limited safety data should be avoided in the first trimester when the risk of congenital malformations is greatest 7, 8

Clinical Decision-Making

• The American Gastroenterological Association suggests that when managing gastrointestinal symptoms requiring prokinetic therapy in the first trimester, a first-line approach should include non-pharmacological management including dietary modifications, adequate hydration, and behavioral adjustments 9
• The American College of Gastroenterology recommends that if medication is necessary, consider safer alternatives with more established safety profiles, such as metoclopramide, which has more extensive pregnancy data 10
• When levosulpiride is being considered, it should be used only when benefits clearly outweigh risks, the lowest effective dose should be employed, and informed consent about limited safety data should be ensured 7, 11

ESC Recommendations for Flecainide Use in Pregnancy

Guideline Recommendation

• The European Society of Cardiology gives flecainide a Class IIa (Level C) recommendation for long‑term management of supraventricular tachycardia (SVT) in pregnancy when first‑line agents such as digoxin or β‑blockers have failed or are contraindicated. 12

Practical Treatment Algorithm (Step 1)

• According to the ESC guideline, the first step in initiating flecainide therapy is to confirm the indication, which includes a highly symptomatic maternal SVT or a fetal tachyarrhythmia associated with hydrops. 12